Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study.
Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, Zhou D, An X, Huang J, Xue C, Bi X, Shi Y, Yuan Z, Xu F, Wang S.
Hong R, et al.
Cancer Commun (Lond). 2021 Feb;41(2):171-182. doi: 10.1002/cac2.12135. Epub 2021 Feb 2.
Cancer Commun (Lond). 2021.
PMID: 33528890
Free PMC article.
Clinical Trial.